BFG
ADMA icon

Bleakley Financial Group’s ADMA Biologics ADMA Stock Holding History

Bleakley Financial Group’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$276K Buy
+32,917
New +$300K ﹤0.01% 897
2026
Q1 		– Sell
-66,354
Closed -$1.21M – 761
2025
Q4 		$1.21M Buy
66,354
+52,562
+381% +$886K 0.02% 438
2025
Q3 		$202K Buy
+13,792
New +$236K ﹤0.01% 585
2025
Q2 		– Sell
-10,697
Closed -$212K – 571
2025
Q1 		$212K Sell
10,697
-6,042
-36% -$104K 0.01% 502
2024
Q4 		$287K Buy
16,739
+6,498
+63% +$122K 0.01% 812
2024
Q3 		$205K Buy
10,241
+37
+0.4% +$575 0.01% 920
2024
Q2 		$114K Sell
10,204
-151
-1% -$1.27K ﹤0.01% 947
2024
Q1 		$68.3K Hold
10,355
– – ﹤0.01% 953
2023
Q4 		$46.8K Sell
10,355
-103
-1% -$381 ﹤0.01% 926
2023
Q3 		$37.4K Sell
10,458
-564
-5% -$2.17K ﹤0.01% 859
2023
Q2 		$40.7K Sell
11,022
-340
-3% -$1.26K ﹤0.01% 904
2023
Q1 		$37.6K Buy
+11,362
New +$39.3K ﹤0.01% 884

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Bleakley Financial Group's ADMA Position: Q2 2026 in Review

Bleakley Financial Group opened a new position in ADMA Biologics (ADMA) in Q2 2026: 32,917 shares worth $276K. The stake represents ﹤0.01% of the portfolio and ranks #897 among its holdings. This is a return to the name: Bleakley Financial Group previously reported a position in ADMA as recently as Q4 2025.

Bleakley Financial Group first reported a position in ADMA in Q1 2023 and has held it in 12 quarters since. The position peaked at $1.21M in Q4 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Bleakley Financial Group held 32,917 shares of ADMA Biologics worth $276K as of Q2 2026.
  • ADMA Biologics was a new Bleakley Financial Group position in Q2 2026.
  • ADMA Biologics made up ﹤0.01% of Bleakley Financial Group's portfolio in Q2 2026, its #897 holding.
  • Bleakley Financial Group first reported a position in ADMA Biologics in Q1 2023 and has held it in 12 quarters since.
  • Bleakley Financial Group's ADMA Biologics position peaked at $1.21M in Q4 2025.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Bleakley Financial Group's 13F filing for Q2 2026, filed 5 Aug 2026.